“…The second approach involves the use of antiidiotypic antibodies. The latter have already been developed against thyroid-stimulating hormone, thyrotropin, insulin, vasopressin, prolactin, substance P, and opioid and dopamine receptors (Sege and Peterson, 1978;Schreiber et al, 1980;Farid et al, 1982;Homcy el al., 1982;Guillet et al, 1984;Shechter et al, 1984;Couraud et al, 1985;Farid, 1985;Ng and Isom, 1985;Amit et al, 1986;Knigge et al, 1987;Swenberg et al, 1987;Hassan et al, 1989;Strosberg, 1989;Mons et al, 1991).…”